Reference
Liang MI, et al. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. Gynecologic Oncology : 27 Dec 2020. Available from: URL: http://doi.org/10.1016/j.ygyno.2020.12.015
Rights and permissions
About this article
Cite this article
Out-of-pocket costs for PARP inhibitors high in US Medicare beneficiaries with ovarian cancer. PharmacoEcon Outcomes News 870, 20 (2021). https://doi.org/10.1007/s40274-021-7423-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7423-7